4BV3
 
 | | CRYSTAL STRUCTURE OF SIRT3 IN COMPLEX WITH THE INHIBITOR EX-527 AND NAD | | Descriptor: | (1S)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1- carboxamide, ADENOSINE-5-DIPHOSPHORIBOSE, CHLORIDE ION, ... | | Authors: | Gertz, M, Nguyen, N.T.T, Weyand, M, Steegborn, C. | | Deposit date: | 2013-06-24 | | Release date: | 2013-07-17 | | Last modified: | 2023-12-20 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | Ex-527 Inhibits Sirtuins by Exploiting Their Unique Nad+-Dependent Deacetylation Mechanism
Proc.Natl.Acad.Sci.USA, 110, 2013
|
|
4BVF
 | | CRYSTAL STRUCTURE OF HUMAN SIRT3 IN COMPLEX WITH THIOALKYLIMIDATE FORMED FROM THIO-ACETYL-LYSINE ACS2-PEPTIDE CRYSTALLIZED IN PRESENCE OF THE INHIBITOR EX-527 | | Descriptor: | 1,2-ETHANEDIOL, ACETYL-COENZYME A SYNTHETASE 2-LIKE, MITOCHONDRIAL, ... | | Authors: | Gertz, M, Weyand, M, Steegborn, C. | | Deposit date: | 2013-06-25 | | Release date: | 2013-07-17 | | Last modified: | 2023-12-20 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Ex-527 Inhibits Sirtuins by Exploiting Their Unique Nad+-Dependent Deacetylation Mechanism
Proc.Natl.Acad.Sci.USA, 110, 2013
|
|
4QDJ
 | |
4QDK
 | |
3ZG0
 | | Crystal structure of ceftaroline acyl-PBP2a from MRSA with non- covalently bound ceftaroline and muramic acid at allosteric site obtained by cocrystallization | | Descriptor: | CADMIUM ION, CHLORIDE ION, Ceftaroline, ... | | Authors: | Otero, L.H, Rojas-Altuve, A, Hermoso, J.A. | | Deposit date: | 2012-12-13 | | Release date: | 2013-10-09 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | How Allosteric Control of Staphylococcus Aureus Penicillin Binding Protein 2A Enables Methicillin Resistance and Physiological Function
Proc.Natl.Acad.Sci.USA, 110, 2013
|
|
3ZFZ
 | | Crystal structure of ceftaroline acyl-PBP2a from MRSA with non- covalently bound ceftaroline and muramic acid at allosteric site obtained by soaking | | Descriptor: | CADMIUM ION, CHLORIDE ION, Ceftaroline, ... | | Authors: | Otero, L.H, Rojas-Altuve, A, Hermoso, J.A. | | Deposit date: | 2012-12-13 | | Release date: | 2013-10-09 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (2.25 Å) | | Cite: | How Allosteric Control of Staphylococcus Aureus Penicillin Binding Protein 2A Enables Methicillin Resistance and Physiological Function
Proc.Natl.Acad.Sci.USA, 110, 2013
|
|
4NKN
 | |
2AK3
 | |
2XQK
 | | X-ray Structure of human butyrylcholinesterase inhibited by pure enantiomer VX-(S) | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, CALCIUM ION, ... | | Authors: | Wandhammer, M, Carletti, E, Gillon, E, Masson, P, Goeldner, M, Noort, D, Nachon, F. | | Deposit date: | 2010-09-02 | | Release date: | 2011-03-23 | | Last modified: | 2023-12-20 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | Structural Study of the Complex Stereoselectivity of Human Butyrylcholinesterase for the Neurotoxic V-Agents.
J.Biol.Chem., 286, 2011
|
|
1MOZ
 | | ADP-ribosylation factor-like 1 (ARL1) from Saccharomyces cerevisiae | | Descriptor: | ADP-ribosylation factor-like protein 1, GUANOSINE-5'-DIPHOSPHATE | | Authors: | Amor, J.C, Horton, J.R, Zhu, X, Wang, Y, Sullards, C, Ringe, D, Cheng, X, Kahn, R.A. | | Deposit date: | 2002-09-10 | | Release date: | 2002-10-09 | | Last modified: | 2024-11-06 | | Method: | X-RAY DIFFRACTION (3.17 Å) | | Cite: | Structures of Yeast ARF2 and ARL1:
DISTINCT ROLES FOR THE N TERMINUS IN THE STRUCTURE
AND FUNCTION OF ARF FAMILY GTPases
J.Biol.Chem., 276, 2001
|
|
4OYJ
 | | Structure of the apo HOIP PUB domain | | Descriptor: | E3 ubiquitin-protein ligase RNF31, SULFATE ION | | Authors: | Elliott, P.R, Komander, D. | | Deposit date: | 2014-02-12 | | Release date: | 2014-05-21 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | Molecular Basis and Regulation of OTULIN-LUBAC Interaction.
Mol.Cell, 54, 2014
|
|
4OGX
 | | Crystal structure of Fab DX-2930 in complex with human plasma kallikrein at 2.4 Angstrom resolution | | Descriptor: | DX-2930 HEAVY CHAIN, DX-2930 LIGHT CHAIN, Plasma kallikrein, ... | | Authors: | Edwards, T.E, Clifton, M.C, Abendroth, J, Nixon, A, Ladner, R. | | Deposit date: | 2014-01-16 | | Release date: | 2014-07-09 | | Last modified: | 2024-11-06 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | Inhibition of plasma kallikrein by a highly specific active site blocking antibody.
J.Biol.Chem., 289, 2014
|
|
2M4Q
 | | NMR structure of E. coli ribosomela decoding site with apramycin | | Descriptor: | APRAMYCIN, RNA (27-MER) | | Authors: | Puglisi, J.D, Tsai, A, Marshall, R, Viani, E. | | Deposit date: | 2013-02-10 | | Release date: | 2013-03-20 | | Last modified: | 2024-05-01 | | Method: | SOLUTION NMR | | Cite: | The impact of aminoglycosides on the dynamics of translation elongation.
Cell Rep, 3, 2013
|
|
4BL3
 | | Crystal structure of PBP2a clinical mutant N146K from MRSA | | Descriptor: | CADMIUM ION, CHLORIDE ION, PENICILLIN BINDING PROTEIN 2 PRIME, ... | | Authors: | Otero, L.H, Rojas-Altuve, A, Carrasco-Lopez, C, Hermoso, J.A. | | Deposit date: | 2013-04-30 | | Release date: | 2014-05-21 | | Last modified: | 2023-12-20 | | Method: | X-RAY DIFFRACTION (3 Å) | | Cite: | Disruption of Allosteric Response as an Unprecedented Mechanism of Resistance to Antibiotics.
J.Am.Chem.Soc., 136, 2014
|
|
4OGY
 | | Crystal structure of Fab DX-2930 in complex with human plasma kallikrein at 2.1 Angstrom resolution | | Descriptor: | 1,2-ETHANEDIOL, DX-2930 HEAVY CHAIN, DX-2930 LIGHT CHAIN, ... | | Authors: | Edwards, T.E, Clifton, M.C, Abendroth, J, Nixon, A, Ladner, R. | | Deposit date: | 2014-01-16 | | Release date: | 2014-07-09 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | Inhibition of plasma kallikrein by a highly specific active site blocking antibody.
J.Biol.Chem., 289, 2014
|
|
4BL2
 | |
3PNW
 | | Crystal Structure of the tudor domain of human TDRD3 in complex with an anti-TDRD3 FAB | | Descriptor: | FAB heavy chain, FAB light chain, Tudor domain-containing protein 3, ... | | Authors: | Loppnau, P, Tempel, W, Wernimont, A.K, Lam, R, Ravichandran, M, Adams-Cioaba, M.A, Persson, H, Sidhu, S.S, Arrowsmith, C.H, Edwards, A.M, Bountra, C, Weigelt, J, Cossar, D, Structural Genomics Consortium (SGC) | | Deposit date: | 2010-11-19 | | Release date: | 2010-12-01 | | Last modified: | 2023-09-06 | | Method: | X-RAY DIFFRACTION (2.05 Å) | | Cite: | CDR-H3 Diversity Is Not Required for Antigen Recognition by Synthetic Antibodies.
J.Mol.Biol., 425, 2013
|
|
9FIQ
 | | Structure-guided discovery of selective USP7 inhibitors with in vivo activity | | Descriptor: | 3-[[4-oxidanyl-1-[(3~{S},4~{S})-3-phenyl-1-(phenylmethyl)piperidin-4-yl]carbonyl-piperidin-4-yl]methyl]quinazolin-4-one, Ubiquitin carboxyl-terminal hydrolase 7 | | Authors: | Baker, L.M, Murray, J, Hubbard, R.E, Whitehead, N. | | Deposit date: | 2024-05-29 | | Release date: | 2024-11-06 | | Method: | X-RAY DIFFRACTION (2.86 Å) | | Cite: | Structure-Guided Discovery of Selective USP7 Inhibitors with In Vivo Activity.
J.Med.Chem., 2024
|
|
9FIR
 | | Structure-guided discovery of selective USP7 inhibitors with in vivo activity | | Descriptor: | 3-[[1-[(2~{S},3~{S})-1-methyl-6-oxidanylidene-2-phenyl-piperidin-3-yl]carbonyl-4-oxidanyl-piperidin-4-yl]methyl]quinazolin-4-one, Ubiquitin carboxyl-terminal hydrolase 7 | | Authors: | Baker, L.M, Murray, J, Hubbard, R.E, Whitehead, N. | | Deposit date: | 2024-05-29 | | Release date: | 2024-11-06 | | Method: | X-RAY DIFFRACTION (2.76 Å) | | Cite: | Structure-Guided Discovery of Selective USP7 Inhibitors with In Vivo Activity.
J.Med.Chem., 2024
|
|
9FIT
 | | Structure-guided discovery of selective USP7 inhibitors with in vivo activity | | Descriptor: | 7-methyl-3-[[4-oxidanyl-1-[(3~{R},4~{R})-3-phenyl-1-[(5-pyrimidin-5-ylthiophen-2-yl)methyl]piperidin-4-yl]carbonyl-piperidin-4-yl]methyl]pyrrolo[2,3-d]pyrimidin-4-one, Ubiquitin carboxyl-terminal hydrolase 7 | | Authors: | Baker, L.M, Murray, J, Hubbard, R.E, Whitehead, N. | | Deposit date: | 2024-05-29 | | Release date: | 2024-11-06 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Structure-Guided Discovery of Selective USP7 Inhibitors with In Vivo Activity.
J.Med.Chem., 2024
|
|
9FIU
 | | Structure-guided discovery of selective USP7 inhibitors with in vivo activity | | Descriptor: | 3-[[1-[(3~{R},4~{R})-1-[5-(3-methoxypyridin-4-yl)thiophen-2-yl]carbonyl-3-phenyl-piperidin-4-yl]carbonyl-4-oxidanyl-piperidin-4-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidin-4-one, Ubiquitin carboxyl-terminal hydrolase 7 | | Authors: | Baker, L.M, Murray, J, Hubbard, R.E, Whitehead, N. | | Deposit date: | 2024-05-29 | | Release date: | 2024-11-06 | | Method: | X-RAY DIFFRACTION (3.37 Å) | | Cite: | Structure-Guided Discovery of Selective USP7 Inhibitors with In Vivo Activity.
J.Med.Chem., 2024
|
|
4J8U
 | |
7JTZ
 | | Yeast Glo3 GAP domain | | Descriptor: | ADP-ribosylation factor GTPase-activating protein GLO3, GLYCEROL, ZINC ION | | Authors: | Xie, B, Jackson, L.P. | | Deposit date: | 2020-08-18 | | Release date: | 2021-03-24 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.07 Å) | | Cite: | The Glo3 GAP crystal structure supports the molecular niche model for ArfGAPs in COPI coats.
Adv Biol Regul, 79, 2021
|
|
4NCG
 | | Discovery of Doravirine, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses | | Descriptor: | 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile, Reverse transcriptase/ribonuclease H, p51 RT | | Authors: | Yan, Y. | | Deposit date: | 2013-10-24 | | Release date: | 2014-02-12 | | Last modified: | 2024-05-22 | | Method: | X-RAY DIFFRACTION (2.58 Å) | | Cite: | Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
Bioorg.Med.Chem.Lett., 24, 2014
|
|
4J8V
 | |
